IBA and Bayer Schering Pharma Sign Clinical Trial Supply Agreement for Alzheimer’s Disease Tracer

31-Aug-2010 - Belgium

IBA (Ion Beam Applications S.A.) announced that they have entered into an agreement with Bayer Schering Pharma AG, Germany (Bayer) for chemical process development and clinical trial doses supply of FLORBETABEN, a molecular imaging compound in development for the detection of Alzheimer’s Disease pathology. The agreement reinforces the companies’ commitment to developing solutions for the early diagnosis and treatment of life threatening diseases.

Under the terms of the agreement, IBA will manufacture and supply Bayer and their trial partners with doses of the compound FLORBETABEN for clinical trials. IBA will develop a large-scale manufacturing process on Synthera®, its proprietary, multi-purpose automated synthesizer, and upgrade its positron emission tomography (PET) manufacturing network in order to ensure availability of the compound for the clinical trials.

Under the terms of the agreement IBA will receive several million Euros (single-digit) of milestone payments and fees depending on the amount of required doses for the clinical trials.

FLORBETABEN is a PET tracer in-licensed by Bayer, undergoing clinical development for potential use in diagnostic imaging of beta-amyloid deposits in the brain, a hallmark of Alzheimer’s Disease.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances